EMC Instytut Medyczny S.A.
- Address
- lock Available on a paid plan
Digestive System Diseases
At EMC Instytut Medyczny S.A. in Wroclaw, clinical research in neurology includes work focused on digestive system diseases, especially hepatic encephalopathy in people with cirrhosis. The studies are designed to evaluate whether new approaches can help delay worsening disease and reduce hospitalizations linked to brain-related complications of liver disease.
- Assessing treatment effectiveness for hepatic encephalopathy
- Reducing the risk of HE-related hospitalization
- Exploring better ways to manage complications of cirrhosis
This area reflects a practical focus on improving day-to-day outcomes for patients living with advanced liver disease, while helping clinicians understand how newer therapies may support disease control.
Female Urogenital Diseases and Pregnancy Complications
The site is also conducting research in female urogenital diseases and pregnancy complications, with attention to sleep disturbances associated with menopause. These trials aim to understand whether a new therapy can improve sleep quality and support symptom relief in women experiencing menopausal changes.
- Evaluating a potential therapy for menopausal sleep disturbances
- Studying improvements in sleep quality and related symptoms
- Generating evidence to support care for women during menopause
Research in this field combines symptom management with quality-of-life goals, offering insight into treatments that may help address a common but often underrecognized problem in women’s health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 9 of 10 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Eli Lilly & Co.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in EMC Instytut Medyczny S.A.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Elinzanetant | 1 | Unknown | 2024-03-14 | 2024-03-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.